Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA‐T2D trial von Groop, Per‐Henrik, Cooper, Mark E., Perkovic, Vlado, Hocher, Berthold, Kanasaki, Keizo, Haneda, Masakazu, Schernthaner, Guntram, Sharma, Kumar, Stanton, Robert C., Toto, Robert, Cescutti, Jessica, Gordat, Maud, Meinicke, Thomas, Koitka‐Weber, Audrey, Thiemann, Sandra, von Eynatten, Maximilian

Volltext

Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME® trial von Kadowaki, Takashi, Nangaku, Masaomi, Hantel, Stefan, Okamura, Tomoo, Eynatten, Maximilian, Wanner, Christoph, Koitka‐Weber, Audrey

Volltext

Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA‐REG OUTCOME trial von Wanner, Christoph, Inzucchi, Silvio E., Zinman, Bernard, Koitka‐Weber, Audrey, Mattheus, Michaela, George, Jyothis T., Eynatten, Maximilian, Hauske, Sibylle J.

Volltext

Short-Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial von Waijer, Simke W, Xie, Di, Inzucchi, Silvio E, Zinman, Bernard, Koitka-Weber, Audrey, Mattheus, Michaela, von Eynatten, Maximillian, Inker, Lesley A, Wanner, Christoph, Heerspink, Hiddo J L

Volltext

Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial von Ferreira, João Pedro, Kraus, Bettina Johanna, Zwiener, Isabella, Lauer, Sabine, Zinman, Bernard, Fitchett, David H, Koitka-Weber, Audrey, George, Jyothis T, Ofstad, Anne Pernille, Wanner, Christoph, Zannad, Faiez

Volltext

Disparate Effects of Diabetes and Hyperlipidemia on Experimental Kidney Disease von Watson, Anna M. D., Gould, Eleanor A. M., Moody, Sarah C., Sivakumaran, Priyadharshini, Sourris, Karly C., Chow, Bryna S. M., Koïtka-Weber, Audrey, Allen, Terri J., Jandeleit-Dahm, Karin A. M., Cooper, Mark E., Calkin, Anna C.

Volltext

Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes von Ruggenenti, Piero, Kraus, Bettina J., Inzucchi, Silvio E., Zinman, Bernard, Hantel, Stefan, Mattheus, Michaela, von Eynatten, Maximilian, Remuzzi, Giuseppe, Koitka-Weber, Audrey, Wanner, Christoph

Volltext

International consensus definitions of clinical trial outcomes for kidney failure: 2020 von Levin, Adeera, Agarwal, Rajiv, Herrington, William G., Heerspink, Hiddo L., Mann, Johannes F.E., Shahinfar, Shahnaz, Tuttle, Katherine R., Donner, Jo-Ann, Jha, Vivekanand, Nangaku, Masaomi, de Zeeuw, Dick, Jardine, Meg J., Mahaffey, Kenneth W., Thompson, Aliza M., Beaucage, Mary, Chong, Kate, Roberts, Glenda V., Sunwold, Duane, Vorster, Hans, Warren, Madeleine, Damster, Sandrine, Malik, Charu, Perkovic, Vlado, Anand, Shuchi, Argent, Nicholas, Babak, Elena, Banerjee, Debasish, Barratt, Jonathan, Bello, Aminu K., Bernardo, Angelito A., Blais, Jaime, Canovatchel, William, Caskey, Fergus J., Coresh, Josef, de Boer, Ian H., Eckardt, Kai-Uwe, Evans, Rhys DR, Feldman, Harold I., Fogo, Agnes B., Gudmundsdottir, Hrefna, Hamano, Takayuki, Harris, David C.H., Hauske, Sibylle J., Haynes, Richard, Herzog, Charles A., Hiemstra, Thomas, Idorn, Thomas, Inker, Lesley, Ishida, Julie H., Johnson, David W., Jones-Burton, Charlotte, Joseph, Amer, Koitka-Weber, Audrey, Kretzler, Matthias, Lawatscheck, Robert, Liew, Adrian, Moist, Louise, Naicker, Saraladevi, Nakashima, Reiko, Patel, Uptal, Filho, Roberto Pecoits, Rose, Jennifer B., Rosenberg, Noah L., Sinsakul, Marvin, Smoyer, William E., Sola, Laura, Sood, Amy R., Stengel, Benedicte, Taal, Maarten W., Tanaka, Mototsugu, Tonelli, Marcello, Tong, Allison, Toto, Robert, Trask, Michele, Ulasi, Ifeoma I., Wanner, Christoph, Wheeler, David C., Wolthers, Benjamin O., Wright, Harold M., Yamada, Yoshihisa, Zakharova, Elena

Volltext

Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOM... von Kraus, Bettina J., Weir, Matthew R., Bakris, George L., Mattheus, Michaela, Cherney, David Z.I., Sattar, Naveed, Heerspink, Hiddo J.L., Ritter, Ivana, von Eynatten, Maximilian, Zinman, Bernard, Inzucchi, Silvio E., Wanner, Christoph, Koitka-Weber, Audrey

Volltext

Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-R... von Cherney, David Z I, Zinman, Bernard, Inzucchi, Silvio E, Koitka-Weber, Audrey, Mattheus, Michaela, von Eynatten, Maximilian, Wanner, Christoph

Volltext

Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories: Post Hoc Analysis of a Randomized, Double-Blind, Placebo-Controlled, Multinational Trial von Levin, Adeera, Perkovic, Vlado, Wheeler, David C, Hantel, Stefan, George, Jyothis T, von Eynatten, Maximilian, Koitka-Weber, Audrey, Wanner, Christoph

Volltext

Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective o... von Mayer, Gert J., Wanner, Christoph, Weir, Matthew R., Inzucchi, Silvio E., Koitka-Weber, Audrey, Hantel, Stefan, von Eynatten, Maximilian, Zinman, Bernard, Cherney, David Z.I.

Volltext

Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial von Cooper, Mark E., Inzucchi, Silvio E., Zinman, Bernard, Hantel, Stefan, von Eynatten, Maximilian, Wanner, Christoph, Koitka-Weber, Audrey

Volltext

Neurovascular Response to Pressure in Patients With Diabetic Foot Ulcer von Vouillarmet, Julien, Josset-Lamaugarny, Audrey, Michon, Paul, Saumet, Jean Louis, Koitka-Weber, Audrey, Henni, Samir, Fromy, Berengere, Sigaudo-Roussel, Dominique

Volltext

Cost-Effectiveness of Empagliflozin in Patients With Diabetic Kidney Disease in the United States: Findings Based on the EMPA-REG OUTCOME Trial von Reifsnider, Odette S., Kansal, Anuraag R., Wanner, Christoph, Pfarr, Egon, Koitka-Weber, Audrey, Brand, Sarah B., Stargardter, Matthew, Wang, Cheng, Kuti, Effie, Ustyugova, Anastasia

Volltext

Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trial von Perkovic, Vlado, Koitka-Weber, Audrey, Cooper, Mark E, Schernthaner, Guntram, Pfarr, Egon, Woerle, Hans J, von Eynatten, Maximilian, Wanner, Christoph

Volltext

Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure: Insights From the EMPA-REG OUTCOME Trial von Butler, Javed, Zannad, Faiez, Fitchett, David, Zinman, Bernard, Koitka-Weber, Audrey, von Eynatten, Maximilian, Zwiener, Isabella, George, Jyothis, Brueckmann, Martina, Cheung, Alfred K., Wanner, Christoph

Volltext

Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial von Wanner, Christoph, Heerspink, Hiddo J L, Zinman, Bernard, Inzucchi, Silvio E, Koitka-Weber, Audrey, Mattheus, Michaela, Hantel, Stefan, Woerle, Hans-Juergen, Broedl, Uli C, von Eynatten, Maximilian, Groop, Per-Henrik

Volltext

Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function von van Bommel, Erik J M, Lytvyn, Yuliya, Perkins, Bruce A, Soleymanlou, Nima, Fagan, Nora M, Koitka-Weber, Audrey, Joles, Jaap A, Cherney, David Z I, van Raalte, Daniël H

Volltext

Kidney Function After Initiation and Discontinuation of Empagliflozin in Heart Failure Patients With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials von Anker, Stefan D., Ponikowski, Piotr, Wanner, Christoph, Pfarr, Egon, Hauske, Sibylle, Peil, Barbara, Salsali, Afshin, Ritter, Ivana, Koitka-Weber, Audrey, Brueckmann, Martina, Lindenfeld, JoAnn, Abraham, William T.

Volltext